

Nicolaas I.L.J. Bohnen, M.D., Ph.D.
Associate Professor of Radiology & Neurology
1500 East Medical Center Drive
University Hospital B1 G505
(734) 936-5388
nbohlen@umich.edu

Title and Contents	Page 1
Education and Training	Page 2
Certification and Licensure	Page 2
Academic, Administrative, and Clinical Appointments	Page 2-3
Research Interests	Page 3
Grants	Page 3-5
Honors and Awards	Page 5
Memberships in Professional Societies	Page 5
Editorial Positions, Boards, and Peer-Review Service	Page 5-6
Teaching	Page 6-7
Committee, Organizational, and Volunteer Service	Page 8
Visiting Professorships, Seminars, and Extramural Invited Presentations	Page 8-10
Bibliography	Page 11-28

Nicolaas I.L.J. Bohnen, M.D., Ph.D.
Associate Professor of Radiology & Neurology
1500 East Medical Center Drive
University Hospital B1 G505
(734) 936-5388

Education and Training

8/73 - 7/79 Bisschoppelijk College Gymnasium B, Cum Laude, Sittard, The Netherlands
8/79 - 7/87 University of Nijmegen, M.D, Medicine, Cum Laude, The Netherlands
9/83 - 6/84 University Sorbonne-Panthéon, Auditeur libre, Faculté de Philosophie & Ecole d'Anthropology, Diplome de l'Ecole d'Anthropology Paris, France
7/87 - 10/91 University of Limburg, Maastricht Ph.D., Neuropsychobiology, The Netherlands. Thesis 1991: "Mild Head Injury and Post-Concussive Sequelae". Advisor: Professor Jelle Jolles.
10/91-6/92 Mayo Clinic, Fellowship in Neuroepidemiology, Department of Health Sciences, Dr. Leonard T. Kurland, M.D., Ph.D., Section of Clinical Epidemiology Rochester, MN
7/92 - 6/93 Mayo Clinic, Preliminary Year in Internal Medicine, Rochester, MN
7/19 - 6/96 Mayo Clinic and Foundation, Residency in Neurology, Rochester, MN
7/96 - 7/98 University of Michigan Medical Center, Ann Arbor, MI, Residency in Nuclear Medicine and Advanced Fellowship in Neurology (Movement Disorders)

Certification and Licensure

Medical or Other Professional Licensure

The Netherlands	1711.6000.18	7/1987
MN	37078	7/1994-7/1997 (inactive)
MI	4301067813	6/1996
PA	MD-065098-L	4/1998

Specialty Certification

American Board of Psychiatry and Neurology (# 44021)	05/1997
American Board of Psychiatry and Neurology Renewal	04/2007
American Board of Nuclear Medicine (#06414)	12/1998
American Board of Nuclear Medicine Renewal	10/2008

Academic, Administrative, and Clinical Appointments

Academic

9/98 - 8/05 University of Pittsburgh Assistant Professor of Departments of Neurology and Radiology, Pittsburgh, PA
9/05 - Present University of Michigan Associate Professor of Departments of Radiology and Neurology, Ann Arbor, MI

Administrative

8/00-8/05 Director Parkinson's disease clinic, VA Medical Center, University Drive, Pittsburgh, PA.
9/04-7/05 R&D Committee, Alternate Chairperson, VA Pittsburgh Healthcare system, Pittsburgh, PA.
9/05-Present Director Parkinson's disease clinic, VA Medical Center, Fuller Road, Ann Arbor, MI

Clinical Appointments

10/98-8/05 Staff Nuclear Medicine Physician & Neurologist, University of Pittsburgh Medical Center, Pittsburgh, PA
10/98-8/05 Staff Neurologist, Veterans Administration and Medical Center, Pittsburgh, PA
4/00-8/05 Staff Nuclear Medicine Physician, Children's Hospital of Pittsburgh, Department of Radiology, Pittsburgh, PA
9/05-Present Staff Neurologist, Veterans Administration and Medical Center, Ann Arbor, MI
9/05-present Staff Researcher, GRECC, Veterans Administration and Medical Center, Ann Arbor, MI
10/05-present Staff Nuclear Medicine Physician & Neurologist, University of Michigan Medical Center Ann Arbor, MI

Research Interests

Functional neuroimaging (positron emission tomography, magnetic resonance imaging), cognitive and mobility assessment of neurodegenerative disorders (Parkinson disease, Alzheimer disease) and normal aging.

Grants

Active

NIH (P01 NS015655-26A10018; PET Study of Biochemistry and Metabolism of the CNS; PI Frey

Role: PI, Clinical Assessment Core.

9/08-6/13; \$1,217,150.

NIH (P01 NS015655-26A19010; PET Study of Biochemistry and Metabolism of the CNS; PI Frey

Role: PI Subproject 2: Serotonergic and cholinergic mechanisms of depression in Parkinson disease.

9/08-6/13; \$272,110.

VA MERIT REHAB REVIEW B4213R:

Striatal and extra-striatal mechanisms of falling in PD

Role: PI

6/06-5/10 \$900,000.

Past

Scaife Family Foundation; Seed Grant

Project: Acetylcholinesterase and Glucose PET Imaging in Parkinsonism and Dementia Period:

Role: PI

2/99-2/00 \$25,000.

VA MERIT REVIEW

Project: Acetylcholinesterase and Glucose PET Imaging in Parkinsonism and Dementia:

Role: PI

7/00-7/03; \$312,600.

VA Competitive Pilot Study;

Project: Acetylcholinesterase and Glucose PET Imaging in Parkinsonism and Dementia Period:

Role: PI

4/99-4/00; \$48,000.

Intra-mural; University of Pittsburgh, Department of Neurology

Title: ^{99m}Tc-ECD brain SPECT normal database project.

Role: PI

Period 1/00-4/04; \$75,000.

Samuel and Emma Winters Foundation; Seed Grant;

Project: Cardiovascular dysautonomia in parkinsonism and dementia;

Role: PI

Period 9/99-9/01; \$5,000.

Veteran Research Foundation of Pittsburgh; Seed Grant;

Project: Striatal D2 receptors and amantadine treatment in parkinsonism and dementia;

Role: PI

Period 1/00-1/01; \$10,000.

The Pittsburgh Foundation;

Project: Striatal D2 receptors and amantadine in Parkinson's disease with neurobehavioral symptoms;

Role: PI

Period 7/00-7/02; \$150,000.

NIA (5P50 AG05133 18): University of Pittsburgh ADRC; PI DeKosky

Role: PI Project 4: Therapeutic correlates of AChE PET imaging in AD;

Period 6/00-6/05; \$416,500.

Scaife Family Foundation; Seed Grant; Effects of unilateral inostrastriatal dopaminergic grafts in MPTP-treated hemiparkinsonian monkeys;

Role: PI

Period 10/00-10/01; \$25,000.

NIH (P01 NS019608; Neuroprotection and compensation; PI Zigmond

Role: PI Project 3 PET, Posturographic and Clinical Markers of Early PD.

Period 5/03-4/08; \$1,025,000.

VA MERIT REHAB REVIEW (E3270R):

Neurobiological and Postural Control Mechanisms Underlying Risk of Falling;

Role: PI

Period 4/04-3/07; \$771,500.

NIA (1 P30 AG024827-01): University of Pittsburgh NIH Claude D. Pepper Older Americans Independence Center, PI Studenski

Role: PI Core Development Project: Executive, Postural Control and Cholinergic Functions in WMD; project part of Dr. Studenski's Pepper Program application;

Period 12/04-11/06; \$60,000

Michael J. Fox Foundation.

Executive, ADL and Cholinergic Functions in PD;

Role: PI

Period 9/05-8/08; \$736,000.

NIA (P30 AG024824-02S1): University of Michigan NIH Claude D. Pepper Older Americans Independence Center, PI: Halter.

Role: PI Core Development Project: Oculomotor bradykinesia, visuospatial attention, dopamine and the risk of falling in the elderly.

Period 9/06-8/31/08; \$66,390.

Honors and Awards

6/1989	Invited for ETP Autumn School (European Science Foundation) 'Biological markers of psychiatric and neurological illness'. Lucca, Italy.
5/1997	Mayo Clinic, Department of Neurology Research Award
1/2003	Invited for the Senior Vice-Chancellor Research Seminar (An Imaging Perspective on the Cholinergic Hypothesis in Dementia)
9/2004	Induction of member to ANA
8/2006	University of Michigan Medical School Clinical Science Scholar

Memberships in Professional Societies

04/1990-6/1992	Dutch Society of Clinical Neurochemistry
08/1992-present	Sigma Xi, The Scientific Research Society (Mayo Foundation Chapter)
02/1993-present	American Academy of Neurology (# 019909)
09/1996-present	American Society of Nuclear Medicine (#201951)
09/2004-present	American Neurological Association, Elected member
12/2004-present	Movement Disorder Society

Editorial Positions, Boards, and Peer-Review Service

8/1996 -	International reviewer for New Zealand Neurological Society	
Nicolaas I.L.J. Bohnen	08/03/09	5

6/1999 - Present	Session Coordinator, Movement Disorders, Society of Nuclear Medicine.
1/1999 - Present	Abstract reviewer, Society of Nuclear Medicine.
4/2001 - Present	Department of Veterans Affairs, Scientific reviewer.
5/2002 - Present	Grant reviewer, Michael J. Fox Foundation
5/2005 - Present	Grant reviewer, MRC (Medical Research Council), United Kingdom.
5/2006 -	External reviewer NIH Claude C. Pepper grants
10/08 -	External reviewer UK Parkinson Disease Society
6/2008 - 6/2009	President-Elect, Brain Imaging Council, Society of Nuclear Medicine
6/2008 -	President, Brain Imaging Council, Society of Nuclear Medicine
6/2009 -	NIH Reviewer (RC-1)

Ad hoc journal reviewer: Annals of Neurology, Archives of Neurology, Biological Psychiatry, Brain, Cerebral Cortex, Cleveland Clinic Journal of Medicine, Clinical EEG and Neuroscience, Drugs & Aging, European Journal of Neurology, European Journal of Nuclear Medicine and Molecular Imaging, Future Drugs, International Journal of Geriatric Psychiatry, International Journal of Neuropsychopharmacology, Journal of the American Geriatric Society, Journal of Cerebral Blood Flow & Metabolism, Journal of Neural Transmission, Journal of Neurology, Journal of Nuclear Medicine, Journal of Vestibular Research, Movement Disorders, Neurobiology of Aging, Neurobiology of Disease, Neuroimage, Neurology, Neuropsychologia, Neuroscience, Neuroscience Letters, Pharmacopsychiatry, Progress in Neurobiology, Psychopharmacology, Synapse.

Teaching Activities

Medical students

1/83-6/83:	Tutor of first year medical students. University of Nijmegen, the Netherlands.
9/1990-6/1991:	Supervisor research assignments medical students, University of Limburg, Maastricht, the Netherlands.
9/1991-6/1992:	Teacher of block 'Head Injury', Neurology, Medical School; Maastricht, the Netherlands.
9/1992-6/1993:	Proctor for medical students; Mayo Medical School.
2/1998-8/2005:	Teacher in Neuroscience course, Medical students MS-II, University of Pittsburgh.
3/1998-8/2005:	Teacher in Clinical Skills Course, Medical Students MS-II, University of Pittsburgh.
9/1998-8/2005:	Teacher Clinical Neurology course, Neurology residents
9/1999-8/2005:	Teacher Nuclear Medicine rounds, Radiology residents
4/2000-8/2005:	Teacher in Neuroscience course, Post-Graduate Students, University of Pittsburgh.
9/2000-8/2005:	Teacher in Clinical Neuroscience Clerkship, Medical Students MS-III-IV, University of Pittsburgh.
3/2002-8/2005:	Teacher in Clinical Neuroscience Integrated Life Sciences Course; Medical Students IV, University of Pittsburgh
5/2004-6/2004:	Teacher in Disabilities Medicine Course; Medical Students I-II,

University of
Pittsburgh
4/2004-5/2004: Teacher in Master of Occupational Therapy (MOT) program,
Parkinson's disease
School of Health and Rehabilitation Sciences, University of Pittsburgh
3/2009-present: Organizer, VA Cognitive & Movement Disorders Clinic, Medical Student
teaching.

Longitudinal clerkship MD/PhD program University of Pittsburgh:

5-6/2000: Sara Berman
1-4/2001: Ted Shulmann

Neurology resident special elective movement disorders:

12/2001: Dr. K. Sumit, MD
1/2002: Raj Katara, MD
2/2002: Scott Shulman, MD
5/2003: Cecile Cole, MD
5/2004: Eugeny Cheltchskov, MD
6/2004: Gad Marshall, MD
2/2005: Salim Qazizadeh, MD
6/2005: Tudor, Iacob, MD

Pediatric neurology resident elective movement disorders:

3/2004: Michele Yang, MD
6/2005: Robert Safier, MD

Neurology fellow:

7/2003-6/2004: Eric Farbman, MD, movement disorders fellow, University of
Pittsburgh & VA movement disorders clinics.

Neurosurgery fellow:

1-4/2001: Camille Salamé, MD
1-4/2003: John Lee, MD

Geriatric medicine fellows St Margaret Hospital:

1/2002: Indu Christopher, MD

Post-graduate Neuroscience students externship:

8-12/2003: Amber Chavanaugh
1-6/2002: Joe Stuckert

Medical student research mentor:

6-8/2005: Peter Syré

Neurology resident research mentors:

2/2002: Uma Pulipaka, MD
4/2003: Eric Farbman, MD
4/2004: Gad Marshall, MD
5/2004: Firas Sioufi, MD

5/2004: Eugeny Cheltchskov, MD
1/2005: Priyantha Herath, MD
5/2005: Satyarana Gedela, MD
4/2009: Vikas Kotagal, MD

Bioengineering research students:

5/2007-6/08 Chris W. Bogan

Mentoring junior faculty:

7/2006-present Martijn Muller, PhD, Research Investigator, Dept. Radiology
9/2008-present Kelvin Chou, MD, Assistant Professor. Depts. Neurology & Neurosurgery
6/2009-present Myria Petrou, MA MBChB MS

Mentoring junior faculty at national level:

8/2009-present Member, Parkinson Study Group (PSG) Mentoring Committee's Advisor Program

Intramural lectures, didactic courses, curriculum development, and other relevant teaching activities See Educator's portfolio

COMMITTEE AND ADMINISTRATIVE SERVICE

Institutional:

9/2002-6/2004 R&D Committee, Alternate member, VA Pittsburgh Healthcare system.
7/2004-6/2005 R&D Committee, Alternate Chairperson, VA Pittsburgh Healthcare system.
9/2006-11/2007 Alternate Member, RDRC/SHUR Committee, IRB University of Michigan.
11/2006- Member, RDRC/SHUR Committee, IRB University of Michigan.
10/2007-present Member, Development Committee, Department of Radiology, University of Michigan.
1/2008-present Chair, RDRC/SHUR Committee, IRB University of Michigan.
11/2008-2/2009 Member, Search Faculty Committee, School of Kinesiology, University of Michigan
6/2009-present Member, PET Operations Committee, Department of Radiology, University of Michigan

Medical School:

Department:

9/1999-8/2005 Member Scientific Review Committee, Department of Neurology, University of Pittsburgh.
11/1999-1/2004 Member Residency Recruitment Committee, Department of Neurology, University of Pittsburgh.

National:

08-10/2003	Department of Veteran Affairs; Special Positron Emission Tomography Advisory Group (SPAG), Washington, DC
12/2004	Department of Veteran Affairs; PET/CT scan advisory group
4/2004:	Review consultant VA MERIT program, Subcommittee for Mental Health and Behavioral Sciences, Department of Veterans Affairs, Washington, DC.
6/1998:	Brain Imaging Council, Society of Nuclear Medicine, Member.
6/2007:	Brain Imaging Council, Society of Nuclear Medicine, Vice-President Elect.
6/2008:	Brain Imaging Council, Society of Nuclear Medicine, Vice-President.
6/2008 -	Committee on Councils, Society of Nuclear Medicine, Member
6/2009:	Brain Imaging Council, Society of Nuclear Medicine, President.

Community service:

5/1999	Greater Pittsburgh Chapter Parkinson Support Group: Update on Parkinson.
3/2001	Pittsburgh South Hills Parkinson's disease support group lecture: "PET imaging in Parkinson's disease."
10/2006	Lansing Parkinson support group lecture "Non-DOPA responsive symptoms in Parkinson disease: Research and new developments".
3/2007:	Ann Arbor Parkinson support group meeting "Non-DOPA responsive symptoms in PD: Research and new developments"
5/2008	Lansing Parkinson support group lecture "Effects of exercise on the brain: Is it applicable to Parkinson's disease?"

Visiting Professorships, Seminars, and Extramural Invited Presentations

1. "PET imaging in dementia" Special lecture, Department of Neurology, Heinrich-Heine Universität, Düsseldorf, Germany, June 5, 1997.
2. "FDG PET imaging of Alzheimer's disease" Special lecture, The Wolfson Brain Imaging Center, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK, June 8, 1997.
3. "Nuclear medicine applications in neurology"; Society of Nuclear Medicine; Pittsburgh Technology Chapter; Pittsburgh, PA, October 28, 2000.
4. "Novel implications of fluorodeoxyglucose imaging in dementia". Second International Workshop on Biomedical Imaging (Fukui-2000), Fukui Medical University, Japan, November 14, 2000.
5. "Functional imaging of striatal disorders". Psychiatry conference Pittsburgh, VA Pittsburgh, PA February 22, 2001.
6. "Management of Parkinson's disease" Lunch with the Professor Workshop. Update in Internal Medicine, University of Pittsburgh, Pittsburgh, PA, November 16, 2001

7. "Toward a Cholinergic Neurobehavioral Model of Dementia in Parkinson's disease"; Seminar, Pittsburgh Institute for Neurodegenerative Disorders, University of Pittsburgh, PA, December 06, 2002
8. "An imaging perspective on the cholinergic hypothesis in dementia", Senior Vice-Chancellor Research Seminar, University of Pittsburgh; Pittsburgh, PA, January 31, 2003
9. "Cognition and cholinergic denervation in Parkinson and Alzheimer disease", Grand Rounds, Department of Neurology, University of North Carolina, Chapel Hill, NC, July 7, 2004.
10. "How do clinical measures and symptoms correlate with the degree of nigrostriatal dopaminergic denervation in Parkinson's disease?"; GRECC noon conference, VA Pittsburgh, Pittsburgh, PA, October 1, 2004.
11. "How do clinical measures and symptoms correlate with the degree of nigrostriatal dopaminergic denervation in Parkinson's disease?" Neurology Grand Rounds, The University of Michigan, Ann Arbor, MI, November 10, 2004.
11. "Dopamine transporter PET imaging and the diagnosis of PD: Do we need PET?" Neurology Grand Rounds, The University of Pittsburgh, Pittsburgh, PA, December 8, 2004.
12. "PET and SPECT brain imaging in dementia evaluation" CME Lecture, Society of Nuclear Medicine Mid Winter meeting Tampa, FL, January 29, 2005.
13. "Subtraction ictal SPECT co-registered to MRI improves clinical usefulness of SPECT in localizing the surgical seizure focus". Workshop, Society of Nuclear Medicine Mid Winter meeting Tampa, FL, January 30, 2005.
14. "Parkinson's disease: Diagnosis and Treatment" CME Lecture, 13th Annual clinical update in Geriatric Medicine, The Pennsylvania Geriatrics Society. Pittsburgh, PA, April 8, 2005.
15. "Biomarker imaging in Parkinson's disease". Categorical lecture, Brain Imaging Council, Society of Nuclear Medicine, San Diego, CA, June 3, 2006.
16. "Cholinergic imaging in neurodegenerative disorders". The 6th Annual Meeting of the International College of Geriatric Psychoneuropharmacology. Hiroshima, Japan, October 6, 2006.
17. "Biomarker imaging in Parkinson disease". Neurology Grand Rounds. Medical College of Ohio, Toledo, OH, November 16, 2006.
18. "Neuroimaging of non-Alzheimer dementia". American Academy of Neurology, Boston, MA, May 5, 2007.
19. "Pharmacological and DBS effects on Parkinson's disease - Effects on movement, cognition and mood" NIA Bedside-to-Bench Conference: Thinking, Moving & Feeling,

Bethesda, MD, September 7, 2007.

20. "From smells to scans: An update on Parkinson disease and diagnosis". Nevada Neuroscience Foundation meeting. Las Vegas, NV, September 15, 2007.
21. "Cognition and depression in Parkinson disease: Challenging the monoaminergic hypothesis". Psychiatry Research Conference, University of California at San Diego, February 25, 2008.
22. "Neuroimaging of non-Alzheimer dementia". American Academy of Neurology, Chicago, IL, April 14, 2008.

BIBLIOGRAPHY

Peer-Reviewed Journals and Publications

1. **Bohnen** N, Houx P, Janknegt R & Jolles J (1989) Effects of an overnight fluid infusion on cognitive functions in preoperative patients. *Int J Neurosci* 48: 233-241.
2. **Bohnen** N, Twijnstra A, Terwel D & Jolles J (1990) Csf arginine-vasopressin decreases during dehydration in a patient with post-traumatic diabetes insipidus. *Horm Metab Res* 22: 508-509.
3. **Bohnen** N, Houx P, Nicolson N & Jolles J (1990) Cortisol reactivity and cognitive performance in a mental task paradigm. *Biol Psychol* 31: 107-116.
4. **Bohnen** N, Nicolson N, Sulon J & Jolles J (1991) Coping style, trait anxiety and cortisol reactivity during mental stress. *J Psychosom Res* 35: 141-147.
5. **Bohnen** N, Twijnstra A, Kroeze J & Jolles J (1991) A psychophysical method for assessing visual and acoustic hyperaesthesia in patients with mild head injury. *Br J Psychiat* 159: 860-863.
6. **Bohnen** N, Twijnstra A, Wijnen G & Jolles J (1991) Tolerance for light and sound of patients with persisting symptoms 6 months after mild head injury. *J Neurol* 238: 443-446.
7. **Bohnen** N, Degenaar C & Jolles J (1992) Influence of age and sex on 19 blood variables in healthy individuals. *Z Gerontol* 25: 339-345.
8. **Bohnen** N, Twijnstra A, Wijnen G & Jolles J (1992) Recovery from visual and acoustic hyperaesthesia following mild head injury in relation to patterns of behavioral dysfunction. *J Neurol Neurosurg Psychiatry* 55: 222-224.
9. **Bohnen** N, Twijnstra A & Jolles J (1992) Performance in the Stroop Color Word Test in relationship to persistence of symptoms following mild head injury. *Acta Neurol Scand*: 85: 116-121.

10. **Bohnen** N, Twijnstra A, Terwel D & Jolles J (1992) Inverse relationship between plasma vasopressin and intracranial pressure. *Horm Metab Res* 24: 141-142.
11. **Bohnen** N, Jolles J & Twijnstra A (1992) Modification of the Stroop Color Word Test improves differentiation between patients with mild head injury and matched controls. *The Clinical Neuropsych* 6: 178-184.
12. **Bohnen** N, Twijnstra A, Jolles J, Mellink R & Sulon J (1992) Coping styles, cortisol reactivity, and performance in a vigilance task of patients with persistent postconcussive symptoms after a mild head injury. *Int J Neurosci* 64: 95-105.
13. **Bohnen** N, Jolles J & Twijnstra A (1992) Neuropsychological deficits in patients with persistent symptoms six months after mild head injury. *Neurosurgery* 30: 692-696.
14. **Bohnen** N, Terwel D, Markerink M, Ten Haaf JA & Jolles J (1992) Pitfalls in the measurement of plasma osmolality pertinent to research in vasopressin and water metabolism. *Clin Chem* 38: 2278-2280.
15. **Bohnen** N, Jolles J & Degenaar CP (1992) Lower levels of vitamin B12 are related to decreased performance on the Stroop color word test in healthy subjects. *Neurosci Res Comm* 11: 53-56.
16. **Bohnen** N & Jolles J (1992) Neurobehavioral aspects of postconcussive symptoms after mild head injury. *J Nerv Ment Dis* 180: 683-692.
17. **Bohnen** N, Twijnstra A & Jolles J (1992) Post-traumatic and emotional symptoms in different subgroups of patients with mild head injury. *Brain Inj* 6: 481-487.
18. **Bohnen** N, Terwel D, Twijnstra A, Markerink M & Jolles J (1992) Effects of apprehension of lumbar puncture procedure on salivary cortisol, plasma vasopressin, and osmolality in man. *Stress Med* 8: 253-257.
19. **Bohnen** N, Jolles J & Verhey FRJ (1993) Persistent neuropsychological deficits in cervical whiplash patients without direct headstrike. *Acta Neurol Belg* 93: 23-31.
20. **Bohnen** N, Twijnstra A & Jolles J (1993) A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma. *Neurology* 43: 103-106.
21. **Bohnen** N, Twijnstra A, & Jolles J (1993) Water metabolism and postconcussional symptoms 5 weeks after mild head injury. *Eur Neurol* 33: 77-79.
22. **Bohnen** N, Twijnstra A & Jolles J (1993) Persistence of postconcussional symptoms in uncomplicated mildly head-injured patients: a prospective cohort study. *Neuropsychiat Neuropsychol Behav Neurol* 6: 193-200.
23. **Bohnen** N, Van Zutphen W, Twijnstra A, Wijnen G, Bongers J & Jolles J (1994) Late outcome of mild head injury: results from a controlled postal survey. *Brain Inj* 8: 701-708.
24. **Bohnen** N, Jolles J & Degenaar CP (1994) Levels of trace elements in blood in healthy

aging subjects. *Z Gerontol* 27: 324-327.

25. **Bohnen** N, Warner MA, Kokmen E, Beard CM & Kurland LT (1994) Alzheimer's disease and cumulative exposure to anesthesia: a case-control study. *JAGS* 42: 198-201.
26. **Bohnen** N, Warner MA, Kokmen E, Beard M & Kurland LT (1994) Prior blood transfusions and Alzheimer's disease. *Neurology* 44: 1159-1160.
27. **Bohnen** N, Warner MA, Kokmen E & Kurland LT (1994) Early and midlife exposure to anesthesia and age of onset of Alzheimer's disease. *Int J Neurosci* 77: 181-185.
28. **Bohnen** N, Jolles J, Twijnstra A, Mellink R & Wijnen G (1995) Late neurobehavioral symptoms after mild head injury. *Brain Inj* 9: 27-33.
29. **Bohnen** N, Wijnen G, Twijnstra A, van Zutphen W, Jolles (1995) The constellation of late post-traumatic symptoms of mild head injury patients. *J Neur Rehab* 9: 33-39.
30. **Bohnen** N, Wijdicks EFM, Warner MA, Kokmen E & Kurland LT (1996) Prior intra operative hypotension is not a risk factor of Alzheimer's disease. *Can J Neurol Sci* 23, 57-58.
31. **Bohnen** N, Ragozzino MW & Kurland LT (1996) Effect of diagnostic radiation during pregnancy on head circumference at birth. *Int J Neurosci* 87: 175-180.
32. **Bohnen** N, Parnell K & Harper CM (1997) Reversible MRI findings in a patient with Hashimoto's encephalitis. *Neurology* 49, 246-247.
33. **Bohnen** N & Shapiro B (1997) Urethro-scrotal fistula presenting as scrotal 'bladder' on bone radionuclide study. *Clin Nucl Med* 22: 864-865.
34. O'Brien TJ, So EL, Mullan BP, Hauser MF, **Bohnen** NI, Hanson D, Jack CR, Cascino GD & Sharbrough MD (1998) Subtraction ictal SPECT co-registered to MRI improves localization of seizure foci. *Neurology* 44:445-454.
35. **Bohnen** N, Beran-Koehn M, Mullan B & Fulgham JR (1998) Crossed cerebro-cerebellar diaschisis in a patient with MELAS but without hemiparesis. *Int J Neurosci* 93: 181-184.
36. **Bohnen** N, O'Brien TJ, Mullan BP & So EL (1998) Cerebellar changes in partial seizures: Clinical correlations of quantitative SPECT and MRI analysis. *Epilepsia* 39: 640-650.
37. Assi Z, **Bohnen** N & Shapiro B (1998) Hepatobiliary scintigraphy in an immunosuppressed patient with hepatocellular dysfunction and acute cholecystitis: Diagnostic dilemmas posed by delayed gallbladder visualization. *Clin Nucl Med* 23: 591-593.
38. **Bohnen** N (1998) Selective anterior amyloid angiopathy and frontal lobe dementia: a clinico-pathologic correlation. *Int J Neurosci* 94:199-204.
39. Meyer P, **Bohnen** N, Shapiro B (1999) Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma. *Nuklearmedizin*: 38: 66-67.

40. **Bohnen** N, Gross MD & Shapiro B (1999) Gallbladder bed photopenic halo on hepatobiliary scintigraphy: a sign of biliary leaking. *Clin Nucl Med*: 24:70-71.
41. Assi Z, **Bohnen** N, Schteingart D, Gross MD, Shapiro B (1999) Testicular I-131 6 β -iodomethyl-19-norcholesterol uptake in a patient with adrenogenital syndrome. *Clin Nucl Med*: 24:464.
42. **Bohnen** N, Minoshima S, Giordani B, Frey KA & Kuhl DE (1999) Motor correlates of occipital hypometabolism in Parkinson's disease without dementia. *Neurology*: 52:541-546.
43. Assi Z, **Bohnen** N, Shulkin B (1999) Paget disease of the thumb. *Clin Nucl Med*: 24:613-614.
44. **Bohnen** N, Frey KA, Albin RL & Fink JK (1999) (+)- α -[¹¹C]DTBZ PET imaging of presynaptic monoaminergic striatal vesicles in familial paroxysmal dystonic choreoathetosis. *Neurology* 52: 1067-1069.
45. Meyer P, **Bohnen** N, Minoshima S, Koeppe R, Wernette K, Kilbourn M, Kuhl DE, Frey KA, Albin RL (1999) Striatal monoaminergic vesicles are not increased in Tourette's syndrome. *Neurology*: 53:371-374.
46. **Bohnen NI**, Charron M, Reyes J, Rubinstein W, Strom S, Swanson D, Towbin RB (2000) Indium-111 labeled hepatocytes for determination of biodistribution of transplanted human hepatocytes via portal vein infusion. *Clin Nucl Med*: 25; 447-450.
47. **Bohnen** N, Koeppe RA, Meyer P, Ficaro E, Wernette, K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL (2000) Decreased Striatal Monoaminergic Terminals in Huntington Disease. *Neurology*: 54;1753-1759.
48. Charron M, Beyer T, **Bohnen** N, Kinahan PE, Dachille M, Jerin J, Nutt R, Meltzer CC, Villemagne V, Townsend DW (2000) Image analysis in oncology patients studied with a combined PET/CT scanner. *Clin Nucl Med*: 25:905-10.
49. **Bohnen NI**, Charron M (2001) Isolated lower extremity I-131 bone marrow uptake in a runner. *Clin Nucl Med*: 26: 163-164.
50. Eidelman BH, Pulipaka U, Wiley C, Charron M, **Bohnen** N (2001) Abnormal cerebral blood flow findings in transplant patients with post-transplant apraxia of speech. *Transpl Proc*: 33(4):2563-5.
51. Constantine G, Chow C, **Bohnen** N (2002) Developing measures of postural rigidity from quiet stance on an electronic platform. *Bull Int Stat Inst*, Tome LIX-2, 147-150.
52. Albin RL, Koeppe RA, **Bohnen** N, Nichols TE, Meyer P, Wernette K, Minoshima S, Kilbourn MR, Frey KA (2003) Increased ventral striatal monoaminergic innervation in Tourette syndrome. *Neurology*: 61:310-315.

53. **Bohnen** NI, Kaufer DI, Ivanco L, Lopresti B, Koeppe RA, Davis J, Mathis CA, Moore RY & DeKosky ST (2003) Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer's Disease: An *In Vivo* PET Study. *Arch Neurol*: 60; 1745-1748.
54. Constantine GM, **Bohnen** N, Chow CC (2004) Electronic platform measures of balance impairment in Parkinsonians and first degree relatives. *Int J Pure Appl Mathematics* 13:259-273.
55. **Bohnen** N, Kaufer D, Hendrickson R, Ivanco L, Moore R, DeKosky S (2004) Effects of Donepezil on Motor Function in Patients with Alzheimer's Disease. *J Clin Psychopharmacology* 24:354-356.
56. **Bohnen** NI, Kaufer, DI, Hendrickson R, Ivanco LS, Lopresti B, Koeppe RA, Meltzer CC, Constantine G, Davis JG, Mathis CA, DeKosky ST & Moore RY (2005) Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 76:315-319.
57. **Bohnen** NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Davis JG, Constantine G, Mathis CA, Moore RY, DeKosky ST (2005) Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. *Neurosci Lett*: 380: 127-132
58. Ivanco LS & **Bohnen** NI (2005) Effects of donepezil on compulsive hypersexual behavior in Parkinson's disease. *Am J Therap*: 12: 467-468.
59. Constantine G, Buliga M, Ivanco L, Moore RY, **Bohnen** N (2005) Predictive models of postural control based on electronic platform measures in patients with Parkinson's disease. *Int J Appl Math* 18:487-500.
60. **Bohnen** N, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis CA, Davis JG, Moore RY, DeKosky ST (2006) Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. *J Neurol*: 253:242-247.
61. Marshall GA, Shchelchkov E, Kaufer DI, Ivanco LS & **Bohnen** NI (2006) White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. *Acta Neurol Scand* 113:87-91.
62. Marshall GA, Hendrickson R, Kaufer DI, Ivanco LS, **Bohnen** NI (2006). Cognitive correlates of brain MRI subcortical signal hyperintensities in non-demented elderly. *Int J Geriatr Psychiatry* 21:32-35.
63. **Bohnen** NI, Albin RL, Koeppe RA, Wernette K, Kilbourn MR, Minoshima S, & Frey KA (2006) Positron emission tomography of striatal monoamine vesicular binding in normal aging and Parkinson's disease. *J Cereb Blood Flow Metab* 26:1198-1212.
64. **Bohnen** NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY (2007) Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. *J Neurol* 254:84-90.

65. **Bohnen** NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY (2007) Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. *J Neurol Neurosurg Psychiatry* 78:641-643.
66. **Bohnen** NI, Frey KA (2007) Imaging of Cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. *Mol Imaging Biol*: 9:243-257.
67. **Bohnen** NI, Kuwabara H, Constantine GM, Mathis CA, Moore RY (2007) Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. *Neurosci Lett*: 424: 185-189.
68. Cham R, Perera S, Studenski SA, **Bohnen** NI (2007) Striatal dopamine denervation and sensory integration for balance in healthy middle-aged and older adults. *Gait and Posture* 26:516-525.
69. Cham R, Studenski SA, **Bohnen** NI (2008) Effects of striatal dopaminergic denervation on gait in middle-aged and elderly subjects. *Exp Brain Res*: 185:391-398.
70. Albin RL, Koeppe RA, **Bohnen** NI, Wernette K, Kilbourn M, Frey KA (2008) Sparing caudal brainstem SERT binding in early Parkinson Disease. *J Cereb Blood Flow Metab* 28:441-444.
71. Wong, K-K, Tolia B, **Bohnen** N (2008) Chronic Sequelae of Herpes Encephalitis demonstrated on interictal ¹⁸F-DG-PET/CT. *Clin Nucl Med: Med* 33:443-444.
72. **Bohnen** NI, Studenski SA, Constantine GM & Moore RY (2008) Diagnostic Performance of Clinical Motor and Non-Motor Tests of Parkinson Disease: A Matched Case-Control Study. *Eur J Neurol*: 15:685-691.
73. **Bohnen** NI, Gedela S, Herath P, Constantine GM & Moore RY (2008) Selective hyposmia in Parkinson disease: Association with hippocampal dopamine activity. *Neurosci Lett* 447:12-16.
74. **Bohnen** NI, Müller MLTM, Kuwabara H, Constantine GM, Studenski SA (2009) Age-associated leukoaraiosis and cortical cholinergic deafferentation. *Neurology* 72:1411-1416.
75. Drag LL, Bieliauskas LA, Kaszniak AW, **Bohnen** NI, Glisky EL (2009) Source memory and frontal functioning in Parkinson's disease. *J Int Neuropsychol* 15:399-406.

Articles Accepted for Publication

1. Ibrahim M, Yousef M, **Bohnen** N, Eisbruch A, Parmar H. Primary Carcinoid Tumor of the Skull Base: Case report and Review of the Literature, *J Neuroimaging*: Accepted.
2. Chou KL, **Bohnen** NI. Performance on an Alzheimer-selective odor identification test in Parkinson's disease and its relationship with cerebral dopamine transporter activity. *Parkinsonism & Relat Disord*: Accepted.

3. **Bohnen** NI, Muller MLTM, Kuwabara H, Cham R, Constantine GM, Studenski SA. Age-associated nigrostriatal dopaminergic denervation and falls in community-dwelling subjects. JRRD: Accepted.
4. **Bohnen** NI, Bogan CW, Muller MLTM. Frontal and periventricular brain white matter lesions and cortical deafferentation of cholinergic and other neuromodulatory axonal projections. ENJ: Accepted.

Invited reviews

1. **Bohnen** N & Kurland LT (1995) Exposure to pesticides and risk of brain tumor in man: a review of the epidemiologic data. J Neurol Sci 132: 110-118.
2. **Bohnen** N, Minoshima S, D. Kuhl, DE & Frey KA (1998) The role of [¹⁸F]-Fluorodeoxyglucose and MRI in the diagnosis of Alzheimer's disease. Neurosci News 1: 26-33.
3. **Bohnen** N (2003) Toepassingen van SPECT en PET in de klinische neurology [Applications of SPECT and PET in clinical neurology] Ned Tijdschr Neurochir Neurol: 104: 339-346.
4. **Bohnen** NI & Frey KA (2003) The role of positron emission tomography imaging in movement disorders. Neuroimag Clin N Am: 63; 791-803.
5. **Bohnen** NI & Cham R (2006) Gait and postural control in parkinsonian movement disorders. Clin Geriatr Med: 22:797-812.

Electronic Publications

1. **Bohnen** N, Frey KA (2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009 updates) Neurochemical and functional brain imaging of movement disorders. In: S Gilman, GW Golstein, SG Waxman (eds). Medlink-Neurobase. San Diego: Arbor Publishing (electronic publication).

Books

1. **Bohnen** N (1991) Mild head injury and postconcussive sequelae. A study of brain and behavior relationships. Krips Repro, Meppel, The Netherlands.

Chapters in Books

1. **Bohnen** N, Terwel D & Wijnen G (1992). The influence of age on plasma sodium and osmolality in healthy individuals after an overnight fast. In: Terwel D, Vasopressin in the brain and plasma of the aging rat. A radioimmunoassay study. Thesis, University of Limburg. University Press Maastricht. The Netherlands, pp. 73-76.

2. Radhakrishnan K, **Bohnen** N & Kurland LT (1993) Epidemiology of brain tumors. In: RA Morantz & JW Walsh (eds). Brain tumors. Marcel Dekker, NY, pp. 1-18.
3. **Bohnen** N & Kurland LT. Epidemiology of brain tumors (1997) In: PJ Vinken & GW Bruyn (eds). Handbook of Clinical Neurology. Vol. 23 (67) Neuro-Oncology, Part I. Elsevier Publishers, Amsterdam: pp. 129-138.
4. **Bohnen** N, Radhakrishnan K, O'Neill BP & Kurland LT (1997) Descriptive and analytic epidemiology of brain tumors. In: P Black & JS Loeffler (eds). Cancer of the Nervous System, 1st Ed. Blackwell Science, Cambridge, pp 1-22.
5. **Bohnen** N (2001) Imagen PET con fluorodesoxiglucosa y de colinesterasa en la enfermedad de Alzheimer [Fluorodeoxyglucose and acetylcholinesterase PET imaging in Alzheimer's disease]. In: JML Lage & ZS Khachaturian (eds). Alzheimer XXI: Ciencia Y Sociedad. Masson, Madrid, pp 229-239.
6. **Bohnen** N (2002) Neurologic applications. In: RL Wahl, JW Buchanan (eds). Principles and practice of positron emission tomography. Lippincott, Williams & Wilkins, Philadelphia, pp. 276-297.
7. **Bohnen** N, Buliga M, Constantine G (2004) Classifying the state of parkinsonism by using electronic force platform measures of balance. In: Banks D, House L, McMorris FR, Arabie P, Gaul W (eds). Classification, Clustering, and Data Mining Applications. Proceedings of the Meeting of the Int Fed Classif Soc (IFCS), Illinois Institute of Technology, Chicago. Springer-Verlag, New York, pp. 477-483.
8. **Bohnen** N, Mountz JM (2006) Epilepsy. In: Charron M (ed). Practical pediatric PET Imaging. Springer, New York, pp. 361-384.
9. **Bohnen** N (2009) Clinical Applications of Positron Emission Tomography in Neurology: Movement disorders, Stroke and Epilepsy. In: RL Wahl (ed). Principles and Practice of PET and PET/CT. Lippincott, Williams & Wilkins, Philadelphia, pp 479-499.

Abstracts

1. Jolles J, Verhey FRJ & **Bohnen** N (1989) Veranderingen in het centrale zenuwstelsel bij veroudering en de gevolgen hiervan op de urineproductie [Changes in the central nervous system with aging and its implications on diuresis]. Ned Tijdschr Geneeskde 133 (36): 1811-1812.
2. **Bohnen** N, Twijnstra A & Jolles J (1990) Persisting post-concussional symptoms and water metabolism. J Neurol (Suppl vol 237): S86-62.
3. Twijnstra A, **Bohnen** N, Terwel D & Jolles J (1990) Plasma vasopressin and fluctuating intracranial pressure. J Neurol (Suppl vol 237): S35:25.
4. **Bohnen** N, Jolles J & Degenaar C (1990) Vitamins, metals and routine blood chemistry in normal aging: results from a multiple cohort study. Neurobiol Aging 11: 336.

5. Jolles J, Houx P, Vreeling FW, **Bohnen** N & Reyersen-van Buuren E (1990) Biological risk factors for accelerated cognitive aging and dementia: findings from a multiple cohort study. *Neurobiol Aging* 11: 293.
6. **Bohnen** N & Jolles J (1990) Cortisol reactivity and cognitive performance in a cognitive stress paradigm. In: *CNS effects of stress hormones and neuropeptides*. Xith International Congress of Pharmacology. Amsterdam: P52.
7. **Bohnen** N, Nicolson N, Sulon J & Jolles J (1991) Coping style, trait anxiety and cortisol reactivity during mental stress. *Annals Behav Med* 13: 4.
8. Wijnen G, **Bohnen** N, Twijnstra A & Jolles J (1992) Coping styles, cortisol reactivity, and performance in a vigilance task of patients with persistent postconcussive symptoms after a mild head injury. *Neurology* 42 (Suppl 3): 280.
9. Twijnstra A, **Bohnen** N & Jolles J (1992) A placebo-controlled trial shows no effect of a vasopressin analogue (DGAVP) on subjective and cognitive recovery immediately after a mild head injury. *Neurology* 42 (Suppl 3): 328.
10. **Bohnen** N, Van Zutphen W, Twijnstra A, Wijnen G & Jolles J (1992) Mild head injury and long-term postconcussive sequelae. *J Neurol* 239 (Suppl 2): S20.
11. **Bohnen** N, Radhakrishnan K, Ragozzino MW, Gray J & Kurland LT (1993) Effects of in utero fetal medical ionizing radiation on head circumference at birth. *Can J Neurol Sci* 20 (Suppl 4): S90.
12. **Bohnen** N & Kurland LT (1995) Risk of seizures in offspring from periconception and in utero medical ionizing radiation. *Neurology* 45 (Suppl 4): A179-180.
13. O'Brien TJ, So EL, Mullan BP, **Bohnen** NI, Jack CR, Cascino GD, Zupanc ML, Hanson DP, Trenerry MR & Sharbrough FW (1996) Extent of resection of the ictal subtraction SPECT focus is an important determinant of epilepsy surgery outcome. *Epilepsia* 37: Suppl 5, 182.
14. **Bohnen** N, O'Brien T, Mullan BP & So EL (1996) Pathogenesis of cerebellar atrophy in epilepsy patients: a study using quantitative subtraction ictal spect and MRI cerebellar volumetry. *Epilepsia* 37: Suppl 5, 201.
15. So EL, O'Brien TJ, Mullan BP, **Bohnen** NI, Jack CR, Cascino GD, Zupanc ML, Hanson DP, Trenerry MR & Sharbrough FW (1996) Seizure localization in intractable partial epilepsy by subtraction ictal SPECT co-registered to MRI: A study of 47 consecutive patients. *Epilepsia* 37: Suppl 5, 124.
16. **Bohnen** N, Cheshire WP, Lennon VA & Van den Berg CJ (1997) Plasma exchange improves function in a patient with ANNA-1 seropositive paraneoplastic autonomic neuropathy. *Neurology* 48: A131.
17. **Bohnen** N, Minoshima S, Giordani B, Frey KA & Kuhl DE (1997) Clinical correlates of occipital hypometabolism in Parkinson's disease without dementia. *JNM* 38 (Suppl): 139.

18. Frey KA, **Bohnen** N, Meyer P, Minoshima S, Wernette K, Koeppe RA, Kilbourn MR, Kuhl DE (1998) Presynaptic monoaminergic vesicles in normal aging studied by (+)-[C-11]DTBZ PET. *J Nucl Med* 39 (Suppl): 15P.
19. **Bohnen** N, Meyer P, Albin RL, Minoshima S, Wernette K, Koeppe RA, Kilbourn MR, Kuhl DE, Frey KA (1998) Clinical correlates of striatal (+)-[C-11]DTBZ binding to VMAT2 in Parkinson's disease. *J Nucl Med* 39 (Suppl): 15P.
20. Frey KA, **Bohnen** N, Meyer P, Elmer L, Albin RL, Koeppe RA, Kilbourn MR, Kuhl DE (1998) (+)-[C-11]DTBZ PET imaging of presynaptic monoaminergic vesicles in isolated postural tremor. *J Nucl Med* 39 (Suppl): 210P.
21. **Bohnen** N, Meyer P, Koeppe RA, Kilbourn MR, Kuhl DE, Frey KA, Albin RL (1998) Decreased striatal monoaminergic terminals in Huntington's disease demonstrated with (+)-[C-11]DTBZ PET. *J Nucl Med* 39 (Suppl): 125P.
22. Meyer P, **Bohnen** N, Minoshima S, Wernette K, Koeppe RA, Kilbourn MR, Kuhl DE, Frey KA, Albin RL (1998) Presynaptic monoaminergic vesicles in Tourette's syndrome studied by (+)-[C-11]DTBZ PET. *J Nucl Med* 39 (Suppl): 202P.
23. So EL, O'Brien TJ, Mullan BF, Hauser MF, Brinkmann BH, **Bohnen** N, Jack CR, Cascino GD & Sharbrough FW (1998) Use of [99m]Tc-ECD for peri-ictal SPECT results in shorter injection latencies and increased localization rates in partial epilepsy: Comparison with [99m]Tc-HMPAO. *Neurology* 50 (Suppl 4): A287.
24. O'Brien TJ, So EL, Mullan BF, Hauser MF, Brinkmann BH, **Bohnen** N, Jack CR, Cascino GD & Sharbrough FW (1998) Detection of localized hypoperfusion by subtraction SPECT co-registered to MRI (SISCOM) improves the sensitivity and specificity of postictal SPECT in intractable partial epilepsy. *Neurology* 50 (Suppl 4): A194.
25. **Bohnen** N, Minoshima S, Giordani B, Rose DS, Frey KA & Kuhl DE (1998) Preclinical evidence of dementia in patients with mild to moderate Parkinson's disease studied by [18F]Fluorodeoxyglucose (FDG) positron emission tomography. *Neurology* 50 (Suppl 4): A182.
26. Frey KA, **Bohnen** NI, Elmer LW, Koeppe RA, Kilbourn MA (1998) Striatal monoaminergic vesicular transporter imaging in Parkinson' disease, essential tremor, and normal aging. *Mov Disord* 13 (5):861.
27. Charron M, **Bohnen** NI, Reyes J, Rubinstein W, Strom S, Swanson D, Towbin RB (1999) Indium-111 labeled hepatocytes for determination of biodistribution of transplanted human hepatocytes via portal vein infusion. *J Nucl Med* 40(Suppl): 189P.
28. **Bohnen** N, Minoshima S, Kilbourn MR, Koeppe RA, Frey KA, Kuhl DE, Albin RL (1999) Presynaptic monoaminergic vesicular transporter imaging in Tourette syndrome using (+)- α -[¹¹C]DTBZ PET. *Neurology* 52 (Suppl 2): A176.
29. Meyer P, **Bohnen** N, Steele J, Koeppe RA, Anzai Y, Kuhl DE, Frey KA, Albin RL (2000) Increased monoaminergic binding in nasal associated lymphoid tissue (NALT) in Tourette syndrome studied with (+)- α -[C-11]DTBZ PET. *J Nucl Med* 41; 216P.

30. Meyer P, **Bohnen** N, Koeppe RA, Kuhl DE, Frey KA, Albin RL (2000) Extra-cerebral retropharyngeal vesicular monoamine transporter binding type 2 in different neuropsychiatric disorders: A (+)- α -[C-11]dihydrotrabenzazine PET study. *Nuklearmedizin* 39;A15.
31. **Bohnen** N, Minoshima S. Novel implications of fluorodeoxyglucose imaging in dementia. Second International Workshop on Biomedical Imaging (Fukui-2000). Fukui Medical University Press, Japan, p. 13.
32. Gardner KL, Pulipaka N, Wieser T, Barmada M, Hendrickson R, McPherson E, **Bohnen** N (2001) X linked recessive syndrome with severe mental retardation, spastic dystonia, seizures, and migraine. *Am J Hum Gen* 69, Suppl. 1: 632.
33. **Bohnen** N, Kaufer D, Lopresti B, Mathis C, Moore RY (2002) *In Vivo* Subcortical Glucose Metabolic and Acetylcholinesterase Activity in Parkinson's Disease with Dementia. *Neurology*: 58(Suppl 3):A354.
34. **Bohnen** N, Kaufer D, Lopresti B, Koeppe R, Meltzer C, Mathis C, Moore RY, DeKosky ST (2002) Clinical, regional cerebral acetylcholinesterase and glucose metabolic changes after donepezil therapy in patients with Alzheimer's disease. *J Nucl Med*: 43: 63P.
35. **Bohnen** N, Kaufer, D, Lopresti, B, Koeppe, R, Mathis, C, Moore RY, DeKosky ST (2002) Cerebral acetylcholinesterase activity in patients with Parkinson's disease with and without dementia and Alzheimer's disease. *J Nucl Med*: 43: 63P.
36. **Bohnen**, N Kaufer, D, Lopresti, B, Mathis, C, Moore, R & DeKosky, S (2003) Brain region-selective inhibition of acetylcholinesterase activity by donepezil in AD. *Neurology*: 60(suppl. 1): A412-413.
37. **Bohnen**, N Kaufer, D, Ivanco, L, Hendrickson, R, Lopresti, B, Mathis, C, DeKosky, ST & Moore, R (2003) Syndromal differences in neurobehavioral correlates of cholinergic denervation in Alzheimer's and Parkinson's disease. *Neurology*: 60(suppl 1): A143.
38. Kaufer DI, **Bohnen** NI, Lopresti B, Mathis CA, Moore RY, DeKosky ST (2003) PET acetylcholinesterase imaging correlates with clinical response to donepezil treatment in Parkinsonian dementia. *Neurology*: 60(suppl. 1):A414.
39. Farbman ES, Ivanco LS, Sunder K & **Bohnen** NI (2003) Orthostatic myeloradiculopathy: Neuroimaging and neurophysiological findings. *Neurology*: 60(suppl 1): A354.
40. **Bohnen** NI, Kaufer DI, Ivanco LS, Hendrickson R, Lopresti B, Davis JG, Mathis CA, Meltzer CC, Moore RY & DeKosky ST (2003) Relationship between Acetylcholinesterase PET Imaging and Clinical Response to Donepezil treatment in Alzheimer's Disease. *J Nucl Med*: 44(suppl):16P.
41. **Bohnen** NI, Kaufer DI, Lopresti B, Davis JG, Mathis CA, DeKosky ST & Moore RY (2003) Cerebral acetylcholinesterase (AChE) activity in patients with Dementia with Lewy Bodies (DLB) and Parkinson's disease with Dementia (PDD). *J Nucl Med*: 44(suppl):213P.

42. **Bohnen** NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Mathis CA, Moore RY & DeKosky ST (2003) Cognitive-behavioral correlates of hemispheric cholinergic denervation in Parkinson's disease without dementia. *J Nucl Med*: 44(suppl):122P.
43. **Bohnen** NI, Kaufer DI, Ivanco LS, Hendrickson R, Lopresti B, Davis JG, Mathis, CA, Moore RY and DeKosky ST (2004) Evidence for clinical threshold effect of donepezil-induced inhibition of cerebral acetylcholinesterase activity in Alzheimer's disease: an *in vivo* PET study. *Neurology* 62 (Suppl 5): A297-A298.
44. **Bohnen** NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Mathis CA, Moore RY, DeKosky ST (2004). Behavioral correlates of variability in cortical cholinergic activity in cognitively normal elderly. *Neurology* 62 (Suppl 5): A296.
44. Marshall GA, Shchelchkov E, Hendrickson R, Kaufer DI, Ivanco LS, Lopresti B, Davis JG, Mathis CA, DeKosky ST, **Bohnen** NI (2004) Cognitive correlates of brain MRI subcortical signal hyperintensities in non-demented elderly. *Neurology* 62 (Suppl 5): A323
46. Marshall GA, Shchelchkov E, Kaufer DI, Ivanco LS, DeKosky ST, Moore RY, **Bohnen** NI (2004) Brain white matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. *Neurology* 62 (Suppl 5): A523-A524.
47. Moore RY, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Mathis CA, DeKosky ST, **Bohnen** NI (2004) Cognitive correlates of cholinergic denervation in Parkinson's disease without dementia. *Neurology* 62 (Suppl 5): A321.
48. Farbman E, Constantine G, Ivanco LS, Ivanco D, Chow C, **Bohnen** NI (2004) Clinical correlates of a biomathematical model of postural sway during quiet stance in patients with Parkinson's disease. *Neurology* 62 (Suppl 5): A207-A208.
49. Kaufer DI, Marshall GA, Hanin I, Lopez OL, **Bohnen** NI, DeKosky ST (2004) Cholinergic correlates of altered awareness in Alzheimer's disease: A clinicopathological study. *Neurology* 62 (Suppl 5): A189.
50. Sioufi F, Ivanco LS, Kaufer DI, Hendrickson R, Lopresti B, Mathis CA, Moore RY, **Bohnen** NI (2004) Striatal dopamine receptor expression in non-demented patients with parkinson's disease with and without neuropsychiatric comorbidity. *Neurology* 62 (Suppl 5): A305.
51. **Bohnen** NI, Kuwabara H, Ivanco LS, Ivanco D, Lopresti B, Hoge J, Mathis CA, Moore RY (2004) Surrogate clinicometric markers of nigrostriatal denervation in Parkinson's disease. *J Nucl Med*: 45(Suppl): 274P.
52. **Bohnen** NI, Sioufi F, Ivanco LS, Hendrickson R, Lopresti B, Mathis CA, Moore RY (2004) Regional striatal D2 activity and neurobehavioral symptoms in Parkinson's disease: a [¹¹C-11]raclopride PET study. *J Nucl Med*: 45(Suppl): 275P.
53. **Bohnen** NI, Sioufi F, Ivanco LS, Mathis CA, Hendrickson R, Moore RY. (2004) Cognitive correlates of dopamine D2 receptor expression in subcortical structures in Parkinson's disease. *J Nucl Med*: 45(Suppl): 72P.

54. Schimmel K, Kuwabara H, Ivanco D, Ivanco LS, Lopresti BJ, Mathis CA, Constantine G, Moore RY & **Bohnen** NI. (2005) Olfactory function is a good biomarker of nigrostriatal denervation in PD. *Neurology*: 64 (Suppl 1): A202.
55. Herath P, Ivanco LS, Constantine G & **Bohnen** NI. (2005) Effects of verbal fluency dual-tasking on postural sway during quiet stance in patients with Parkinson's disease: *Neurology*: 64 (Suppl 1):A395-A396.
56. Kaufer DI, **Bohnen** NI, Ivanco L, Hendrickson R, Lopresti B, Mathis CA, Moore RA & DeKosky ST. (2005) Cortical cholinergic deficits and neuropsychiatric disturbances in Parkinson's disease with and without dementia. *Neurology*: 64 (Suppl 1): A137-A138.
57. **Bohnen** NI, Kaufer DI, Ivanco LS, Hendrickson R, Lopresti B, Mathis CA, Moore RY & DeKosky ST. (2005) Cholinergic denervation is associated with more severe depression in Parkinson's Disease: *Neurology*: 64 (Suppl 1): A222.
58. **Bohnen** NI, Schimmel K, Ivanco LS, Ivanco D, Lopresti BJ, Mathis CA, Moore RY. (2005) Olfactory function has good discriminatory function between subjects clinically diagnosed as Parkinson's Disease (PD) with and without evidence of nigrostriatal dopaminergic denervation. *J Nucl Med* 46 (Suppl 2): 296P.
59. **Bohnen** NI, Schimmel K, Ivanco LS, Ivanco D, Lopresti BJ, Mathis CA, Moore RY. (2005) Nigrostriatal dopaminergic denervation as a model of Parkinson's disease is insufficient to explain the full clinical parkinsonian syndrome: a ¹¹C-β-CFT PET study. *J Nucl Med* 46 (Suppl 2): 65P.
60. **Bohnen** NI, Kuwabara H, Schimmel K, Ivanco LS, Lopresti BJ, Mathis CA, Moore RY, Constantine G. (2005) Anteroposterior but not posterolateral sway robustly predicts the striatal dopaminergic deficit in Parkinson's disease. *Ann Neurol*: 58 (Suppl 9): S53.
61. Herath P, Ivanco LS, **Bohnen** NI. (2005) Ictal cerebral blood flow findings and therapeutic response to donepezil in a patient with Tourette syndrome and tactile reflex tics. *Ann Neurol* 58 (Suppl 9): S53-S54.
62. Ivanco LS, Kaufer DI, Hendrickson R, **Bohnen** NI. (2005) Development of a "mental rigidity" rating scale in patients with Parkinson's disease. *Ann Neurol* 58 (Suppl 9): S6.
63. **Bohnen** NI, Studenski SA, Schimmel K, Ivanco D, Ivanco LS, Constantine G, Moore RY. (2006) Composite motor and olfactory test battery can be used as a screening instrument for the diagnosis of Parkinson's disease in the general population. *Neurology (suppl)*: 66(Suppl 2): A234.
64. Moore RY, Ivanco LS, Schimmel K, Ivanco DE, Constantine G, **Bohnen** NI. (2006) The detection rate of nigrostriatal dopaminergic denervation in minimally symptomatic first degree relatives of patients with Parkinson's disease is low. *Neurology (suppl)*: 66(Suppl 2):S20:002.

65. Ivanco LS, Schimmel K, Hendrickson R, **Bohnen** NI. (2006) Ratings of “mental rigidity” and striatal dopamine transporter activity in patients with Parkinson’s disease. *Neurology* 66(Suppl 2):A207.
66. Ivanco LS, Kaufer DI, Hendrickson R, **Bohnen** NI. (2006) Modification of the Stroop Color Word Test better defines the executive cognitive deficit in non-demented patients with Parkinson’s disease. *Neurology (suppl)*: 66(Suppl 2):A51.
67. **Bohnen** NI, Gedela S, Ivanco LS, Schimmel K, Ivanco DE, Constantine G, Moore RY. (2006) Selective pattern of hyposmia has better correlation with nigrostriatal dopamine transporter activity than motor impairment in Parkinson’s disease. *Neurology* 66(Suppl 2):A125.
68. **Bohnen** NI, Schimmel K, Ivanco LS, Mathis CA, Moore RY (2006) Clinical motor functions have more robust correlations with ventral compared to dorsal putaminal dopamine transporter activity in Parkinson’s disease. *J Nucl Med* 47(Suppl 5): 305-306P.
69. **Bohnen** NI, Ivanco LS, Schimmel K, Ivanco DE, Mathis CA, Moore RY, Studenski SA. (2006) Functional significance of age-associated nigrostriatal denervation in healthy subjects. *J Nucl Med* 47(Suppl 5): 210P.
70. McNeal A, Chambers AJ, Cham R, **Bohnen** NI (2006) Aging-related dopamine denervation in the basal ganglia and balance in sway-referenced visual environments. American Society Biomechanics Conference (Blacksburg, VA, September 6-9, 2006).
71. **Bohnen** NI, Studenski SA, Moore RY (2006) Prediction of disease state in Parkinson disease by motor versus non-motor tests. The 6th Annual Meeting of the International College of Geriatric Psychoneuropharmacology. Hiroshima, Japan, p. 113.
72. Schimmel K, Herath P, Ziolk S, Lopresti B, Mathis C, Moore R, **Bohnen** N. (2006) Cortical C-11-β-CFT dopamine transporter activity is asymmetrically reduced and lateralizes to the clinically most affected body side in Parkinson’s disease. *Ann Neurol* 60(Suppl 10): S80.
73. Herath P, Ivanco L, **Bohnen** N. (2006) Sitting and standing cognitive performance in patients with Parkinson's disease. *Ann Neurol* 60(Suppl 10): S48.
74. Herath P, Schimmel K, Ivanco L, Price J, Ziolk S, Kaufer D, Dekosky S, **Bohnen** N. (2006) Glucose metabolic response to donepezil therapy in patients with Alzheimer’s disease (AD) in relation to degree of acetylcholinesterase (AChE) inhibition. *Ann Neurol* 60(Suppl 10): S32.
75. Herath P, Syré P, Ziolk S, Schimmel K, Constantine G, Studenski SA, **Bohnen** NI. (2007) Falls in community-dwelling elderly are associated with severity of leukoaraiosis. *Neurology* 68 (Suppl 1): A226.
76. Herath P, Syré P, Ziolk S, Schimmel K, Constantine G, Studenski SA, **Bohnen** NI. (2007) Slowing of gait speed is related to frontal white matter lesions but not to loss of striatal dopamine in the elderly. *Neurology* 68 (Suppl 1): A174.

77. Moore RY, Kuwabara H, **Bohnen** NI. (2007) Clinical biomarkers of striatal dopaminergic denervation in Parkinson disease. *Neurology* 68 (Suppl 1): A356.
78. Moore RY, Ziolk S, Schimmel K, Syré P, Constantine G, Studenski SA, **Bohnen** NI. (2007) Presence of mild parkinsonian-like symptoms in normal aging reflects nigrostriatal dopaminergic denervation rather than leukoaraiosis. *Neurology* 68 (Suppl 1): A330.
79. Muller ML, Kuwabara H, Constantine G, Moore RY, **Bohnen** NI. (2007) Postural sway as a biomarker of dopaminergic denervation in patients with mild Parkinson's disease. *J Nucl Med* 48 (suppl 2): 9P.
80. **Bohnen** NI, Kuwabara H, Constantine G, Mathis CA, Muller ML, Moore RY. (2007) Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson disease: Most versus less affected side. *J Nucl Med* 48 (suppl 2): 253P.
81. Muller ML, Constantine G, Moore RY, **Bohnen** NI (2007) Postural sway and striatal dopaminergic denervation in Parkinson disease and healthy aging adults. *Gait and Posture* SP-8.
82. Cham R, Perera S, Studenski SA, **Bohnen** NI (2007) Striatal dopaminergic denervation and modulation of temporal gait variability. *Gait and Posture* TO-17.
83. Herath P, Gedela S, Ivanco L, Moore R, **Bohnen** N (2007) Selective hyposmia in Parkinson disease is more robustly associated with hippocampal than striatal dopaminergic denervation. *Ann Neurol* 62 (Suppl 11): S35.
84. Muller MLTM, Studenski SA, **Bohnen** NI (2008) Fall history is associated with severity of white matter changes but not striatal dopaminergic denervation. *Parkinsonism & Related Disorders* Vol 14 (Suppl 1): S5.
85. Cham R, Studenski SA, Perera S, **Bohnen** NI. (2008) Aging-related striatal dopaminergic denervation, balance and gait in healthy adults. *Parkinsonism & Related Disorders* Vol 14 (Suppl 1): S46.
86. Moore RY, Gedela S, Studenski SA, **Bohnen** NI. (2008) Performance on an Alzheimer-Selective Odor Identification Test in Patients with Parkinson Disease. *Neurology* 70 (Suppl 1): A280.
87. **Bohnen** NI, Muller MT, Syré P, Ziolk S, Studenski SA (2008) Basal Ganglia MRI Hyperintensities and Falls in Community-Dwelling Elderly. *Neurology* 70 (Suppl 1): A68.
88. **Bohnen** NI, Gedela S, Studenski SA, Moore RY (2008) Olfaction is Preserved in Subjects with Clinical Parkinson Disease but without evidence of Nigrostriatal Denervation. *Neurology* 70 (Suppl 1): A398.
89. **Bohnen** NI, Albin RL, Koeppe RA, Muller MT, Kilbourn MA, Frey KA. (2008) Selective hyposmia and striatal monoaminergic vesicular binding in Parkinson disease. *J Nucl Med* 49(Suppl 1): 221P.

90. **Bohnen** NI, Koeppe RA, Minoshima S, Giordani B, Frey KA, Kuhl DE. (2008) Cognitive correlates of posterior cingulate hypometabolism in Parkinson disease. *J Nucl Med* 49 (Suppl 1): 220-221P
91. **Bohnen** NI, Koeppe RA, Minoshima S, Giordani B, Frey KA, Kuhl DE. (2008) Posterior cortical hypometabolism precedes mixed subcortical-cortical metabolic changes in incident dementia in Parkinson disease. *J Nucl Med* 49(Suppl 1): 6P.
92. **Bohnen** NI, Frey KA, Koeppe RA, Muller MT, Kilbourn MA, Albin RL. (2008) Cerebellar acetylcholinesterase activity and parkinsonian motor impairment. *J Nucl Med* 49(Suppl 1): 222P.
93. Kuwabara H, Muller, MT, **Bohnen** NI. (2008) A constrained analysis improved estimates of acetylcholinesterase density with [¹¹C]PMP and PET. *J Nucl Med* 49(Suppl 1): 118P.
94. O'Loughlin M, Chambers AJ, Studenski SA, **Bohnen** NI, Cham R. (2008) Striatal dopamine denervation and peak slip velocity during gait. *BMES*.
95. Bogan C, **Bohnen** N, Koeppe R, Frey K, Albin R, Muller M. (2008) Age-associated dopaminergic influences on foot-tapping and temporal gait parameters in healthy older adults. *Proceedings North American Congress on Biomechanics, Ann Arbor, MI, August 5-9; Abstract 372.*
96. Kwak Y, Muller MLTM, **Bohnen** NI, Dayalu P, Huismann DJ, Seidler RD. (2008) Impaired early learning of explicit motor sequences by dopaminergic medications in Parkinson's disease. *Neuroscience: Accepted.*
97. Kwak Y, Muller MLTM, **Bohnen** NI, Huismann DJ, Seidler RD (2008) Impaired early learning of explicit motor sequences by dopaminergic medications in Parkinson's disease. *Mov Disord* 23(suppl):S100.
98. Chou KL, **Bohnen** NI (2008) Parkinson's disease patients with rhinorrhea have better olfaction than patients without rhinorrhea. *Mov Disord* 23(suppl): S290-S291.
99. Kotagal V, Muller MT, Koeppe RA, Frey KA, Albin RL, **Bohnen** NI (2009) Executive dysfunction in Parkinson's disease is more closely associated with cortical cholinergic than with nigrostriatal dopaminergic denervation. *Neurology* 72 (suppl 3): A264-A265.
100. Kotagal V, Muller M, Koeppe RA, Frey KA, Albin RL, **Bohnen** NI (2009) Parkinson and Alzheimer-selective hyposmia measures have different neurochemical substrates in patients with Parkinson's disease. *Neurology* 72 (suppl 3): A146.
101. **Bohnen** NI, Muller MLTM, Koeppe RA, Frey KA, Albin RL (2009) Postural Instability and Gait Difficulty (PIGD) Score is independently associated with both Cerebellar Cholinergic and Nigrostriatal Dopaminergic Activity In PD. *Neurology* 72 (suppl 3): A166.

102. **Bohnen** NI, Muller MLTM, Kuwabara H, Constantine GM, Studenski SA (2009) Age-associated leukoariosis and cortical cholinergic deafferentation. *Neurology* 72 (suppl 3): A436.
103. **Bohnen** NI, Frey KA, Muller MLTM, Koeppe RA, Kilbourn MA, Albin RL (2009) History of falls in Parkinson disease is associated with reduced cholinergic but not nigrostriatal dopaminergic activity. *J Nucl Med* 50 (suppl 2): 234P.
104. Bogan CW, Muller MLTM, Koeppe RA, Kilbourn MA, Albin RL, Frey KA, **Bohnen** NI (2009) Variability in foot-tapping as a new biomarker of nigrostriatal denervation in Parkinson's disease. *J Nucl Med* 50 (suppl 2): 34P.
105. **Bohnen** NI, Muller MLTM, Koeppe RA, Kilbourn MA, Albin RL, Frey KA (2009) Heterogeneity of neurodegeneration in Parkinson disease: variable degree of dopaminergic versus cholinergic denervation. *J Nucl Med* 50 (suppl 2): 34P.
106. **Bohnen** NI, Muller MLTM, Koeppe RA, Kilbourn MA, Frey KA, Albin RL (2009) Ratings of activities of daily living are associated with cortical cholinergic but not with the degree of nigrostriatal dopaminergic activity in Parkinson disease. *J Nucl Med* 50 (suppl 2): 238P.
107. Bogan CW, Muller MLTM, Ma Y, Eidelberg D, **Bohnen** NI (2009) Associations between a measure of brain network metabolic activity and non-motor measures of Parkinson's disease. *J Nucl Med* 50 (suppl 2): 237P.
108. Bogan CW, Muller MLTM, Kuwabara H, Cham R, Constantine GM, Studenski SA, **Bohnen** NI (2009) Age-associated nigrostriatal dopaminergic denervation and falls in community-dwelling subjects. *J Nucl Med* 50 (suppl 2): 236P.
109. Bogan CW, Muller MLTM, Ma Y, Eidelberg D, **Bohnen** NI (2009) Feasibility of Carbon-11-Dihydrotetrabenazine ligand influx images in a principal component based analysis. *J Nucl Med* 50 (suppl 2): 278P.
110. Muller M, Albin R, Koeppe R, Frey K, **Bohnen** N (2009) Monoaminergic and cholinergic correlates of falling in Parkinson disease. *ISPGR*: Accepted.
111. Wong KK, **Bohnen** N, Brown RK, Frey KA (2009) Cerebral ¹⁸F-FDG PET Imaging of Neurodegenerative Disorders: Diagnostic Patterns with Statistical Parametric Mapping. *EANM*: Accepted.

Letters, Editorials, Book Reviews, and Miscellaneous:

1. **Bohnen** NI (1994) Pesticides and brain tumour. *Int J Epidemiol* [letter] 23: 867.
2. **Bohnen** NI, Warner MA, Kokmen E, Beard CM & Kurland LT (1994) Alzheimer's disease and anesthetic exposure. *JAGS* [letter] 42: 908-909.

3. **Bohnen** NI (1994) Technique of the neurologic examination: a programmed text, 4th ed, by William E. DeMeyer, NY, McGraw Hill. Mayo Clin Proc [Book review] 69: 1019.
4. Assi Z, **Bohnen** N & Shapiro B (1999) Hepatobiliary scintigraphy in an immunosuppressed patient with hepatocellular dysfunction and acute cholecystitis: Diagnostic dilemmas posed by delayed gallbladder visualization. In: The Year Book of Nuclear Medicine, Gottschalk, A (ed), Mosby, St. Louis, pp. 225-226 [Paper discussion]
5. **Bohnen** NI & Albin RL (2009) Cholinergic denervation occurs early in Parkinson disease. Neurology [editorial]73:256-257.